Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date

• Main Authors: Alkabbani W, Gamble JM
• Format: Article
• Language: English
• Published: Dove Medical Press 2021-07-01
• Series: Drug Design, Development and Therapy
• Subjects: review; efficacy; safety; pharmacokinetics; pharmacodynamics; discovery
• Online Access: https://www.dovepress.com/profile-of-ipragliflozin-an-oral-sglt-2-inhibitor-for-the-treatment-of-peer-reviewed-fulltext-article-DDDT

Wajd Alkabbani, John-Michael Gamble School of Pharmacy, Faculty of Science, University of Waterloo, Kitchener, ON, CanadaCorrespondence: John-Michael GambleSchool of Pharmacy, Faculty of Science, University of Waterloo, 10A Victoria Street S, Kitchener, ON, N2G 1C5, CanadaTel [phone]Fax [phone]Email [e-mail]: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a novel class of pharmacotherapeutics for type 2 diabetes management that work by reducing renal reabsorption of glucose. Ipragliflozin is a potent, selective SGLT-2 inhibitor used for the management of type 2 diabetes.Objective: The primary aim of this review is to summarize the available evidence on the efficacy and safety of ipragliflozin for the management of type 2 diabetes. We also review the discovery, pharmacokinetic, and pharmacodynamic profile of ipragliflozin.Methods: To inform our review, we searched MEDLINE, International Pharmaceutical Abstracts, and Embase to identify relevant papers to ipragliflozin use in type 2 diabetes. Clinical trial registries were also searched.Results: Findings from randomized clinical trials demonstrate that compared to placebo, ipragliflozin significantly reduces glucose as measured via Hemoglobin A1c and fasting plasma glucose levels. Ipragliflozin is also associated with weight reduction and an improvement in some, but not all, cardiovascular risk markers. Ipragliflozin has a favourable safety profile with a low risk of hypoglycemia and the rates of common adverse events are not significantly different than placebo. Limited data are available to assess rare and long-term adverse effects.Conclusion: Current evidence shows that ipragliflozin is an effective therapeutic option for the management of glucose control in type 2 diabetes. However, no cardiovascular outcome trials have been conducted to date. Real-world observational studies are still needed to accurately capture any possible rare or long-term adverse events.Keywords: review, efficacy, safety, pharmacokinetics, pharmacodynamics, discovery